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Abstract
Withaferin A (WFA) is a natural product that binds to soluble forms of the type III intermediate filament (IF) vimentin.
Currently, it is unknown under what pathophysiological contexts vimentin is druggable, as cytoskeltal vimentin-IFs are
abundantly expressed. To investigate druggability of vimentin, we exploited rabbit Tenon’s capsule fibroblast (RbTCF) cell
cultures and the rabbit glaucoma filtration surgical (GFS) model of fibrosis. WFA potently caused G0/G1 cell cycle inhibition
(IC50 25 nM) in RbTCFs, downregulating ubiquitin E3 ligase skp2 and inducing p27
Kip1 expression. Transforming growth
factor (TGF)-ß-induced myofibroblast transformation caused development of cell spheroids with numerous elongated
invadopodia, which WFA blocked potently by downregulating soluble vimentin and a-smooth muscle actin (SMA)
expression. In the pilot proof-of-concept study using the GFS model, subconjunctival injections of a low WFA dose reduced
skp2 expression in Tenon’s capsule and increased p27Kip1 expression without significant alteration to vimentin-IFs. This
treatment maintains significant nanomolar WFA concentrations in anterior segment tissues that correspond to WFA’s cell
cycle targeting activity. A ten-fold higher WFA dose caused potent downregulation of soluble vimentin and skp2
expression, but as found in cell cultures, no further increase in p27Kip1 expression was observed. Instead, this high WFA dose
potently induced vimentin-IF disruption and downregulated a-SMA expression that mimicked WFA activity in TGF-ß-treated
RbTCFs that blocked cell contractile activity at submicromolar concentrations. These findings illuminate that localized WFA
injection to ocular tissues exerts pharmacological control over the skp2-p27Kip1 pathway by targeting of soluble vimentin in
a model of surgical fibrosis.
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Introduction
The type III intermediate filaments (IFs) are a family of
cytoskeletal proteins that display dynamic and complex expression
as both soluble and polymeric proteins [1,2,3,4]. Only recently,
these IFs have emerged as a novel class of druggable targets
[5,6,7,8,9,10], a discovery borne out from a forward chemical
genetic screening expedition investigating the binding protein
targets of the anti-angiogenic natural product withaferin A (WFA)
[5]. WFA was shown to bind and downregulate the soluble forms
of vimentin in human vascular endothelial cells, and interestingly,
this finding led further to the illumination that the WFA-binding
site in tetrameric vimentin was conserved evolutionarily from
humans to sharks [7]. This revelation drew our attention to WFA
not only as a potent pharmacological agent but also to it’s use as a
chemical probe for interrogating biological signaling pathways that
are linked to vimentin functions. Recognizing that vimentin, and
in general the type III IFs, have roles in injury repair because of
their mechanosensory functions [3,11], we exploited a corneal
alkali injury model to investigate vimentin targeting by WFA. This
study demonstrated that vimentin overexpression in injured
corneal tissues was downregulated by WFA resulting in potent
inhibition of corneal neovascularization and scarring with
consequential restoration of corneal transparency [7]. Further-
more, vimentin-deficient (Vim KO) mice were also protected
against corneal fibrosis in the alkali injury model lending evidence
that vimentin is the druggable target [7]. Together, these studies,
along with several other findings made in other systems have
illustrated vimentin involvement in epithelial mesenchymal
transition [12,13] and point to a central pathological role for
vimentin overexpression in fibrotic events.
WFA exerts distinct dose-dependent inhibitory activities on
cellular processes related to angiogenesis and fibrotic repair. At
low nanomolar concentrations, WFA exerts G0/G1 cell cycle
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arrest (IC50 = 12 nM in endothelial cells) [14]. This cytostatic
mechanism involves the expression of cyclin-dependent kinase
inhibitor p27Kip1, which was also observed in the mouse alkali-
injury model of corneal fibrosis when animals were treated with
WFA [7]. The perturbation of the cell cycle results from WFA’s
downregulation of the ubiquitin E3 ligase, skp2. This downreg-
ulation alleviates the proteasome-mediated degradation of
p27Kip1, which is a target of skp2, and promotes corneal cell
cycle arrest. That this skp2-p27Kip1 pathway is critical to WFA’s
cell cycle-targeting mechanism was illustrated in embryonic
fibroblasts derived from either skp2-deficient or p27Kip1-deficient
mice that showed resistance to cell cycle blockade after treatement
with WFA when compared to wild-type cells [7]. At higher
concentrations in the submicromolar range, WFA also inhibits cell
migration and cell invasion (IC50 500 nM), which are critical for
endothelial cell sprouting in three-dimensional collagen gel
spheroid angiogenic assays [14,15,16]. Over this higher submi-
cromolar concentration range, WFA also perturbs the vimentin-IF
cytoskeleton causing the polymeric forms to condense at the
perinuclear region with ensuing cell shape changes as a result of
cytoskeletal retraction [5,17,18]. Above 2 mM WFA induces
extensive perturbation of the IF-cytoskeleton, fragmentation of
F-actin and induction of apoptosis, which is a critical mechanism
for cancer chemotherapeutics [8,9]. As such, the low nanomolar
effects of WFA on soluble IFs are not detectable by immunohis-
tochemical methods because soluble IFs represent less than 5–10%
of total IF protein pool in most primary cell cultures. However,
growth-arrested cells stimulated to enter the cell cycle have a
significantly larger pool of tetrameric vimentin that rapidly
undergo polymerization into filamentous forms upon cell cycle
entry; it is at this cell cycle stage that WFA exerts its most potent
inhibitory activity on cell proliferation [6,7,14]. Appreciating that
such dynamic states for soluble and polymeric vimentin have also
been reported in different biological contexts
[2,19,20,21,22,23,24,25,26], the vulnerability of soluble vimentin
[1] in living tissues to WFA’s pharmacological activity has
remained poorly characterized.
The importance of vimentin expression is especially relevant to
wound repair [27,28]. Vim KO mice display delayed wound
healing when subjected to full thickness skin injury, but these mice
are otherwise normal and fertile. This phenotype is characterized
by a delay in myofibroblast influx at the wound site, which results
from deficiencies in cell migration and contractile forces necessary
to seal an open wound [28]. Whereas complete absence of
vimentin may not be desirable for wound repair in vascularized
tissues, the benefit of reduced myofibroblast involvement and
attenuated cell proliferation promoted by pharmacological down-
regulation of vimentin offers therapeutic advantages because
conditional control of target expression can be pharmacodynam-
ically modulated [7]. However, to investigate vimentin drugg-
ability in ocular models of injury repair, a localized delivery
method to evaluate WFA activity in vivo would be more clinically
relevant, because this strategy also avoids systemic effects [29].
Glaucoma filtration surgery (GFS) is a procedure used to
alleviate increased intraocular pressure in patients who have high-
tension glaucoma [30]. The procedure involves creating an
alternative passage to bypass blocked or failing trabecular
meshwork. The success of this surgical procedure is compromised
when excessive cell proliferation in Tenon’s capsule by fibroblasts
causes the surgical bleb to develop scar tissue [31]. A key pro-
fibrogenic factor found elevated during glaucoma wound repair is
the cytokine transforming growth factor (TGF)-b [31,32]. Expo-
sure to TGF-b expression after GFS can cause scarring by
recruiting Tenon’s capsule fibroblasts to differentiate into myofi-
broblasts and exert contractile activity [33,34]. Treatment of
human trabecular meshwork cells with TGF-b1 or TGF-b2
promotes strong overexpression of vimentin [33]. Vimentin
overexpression has been implicated in the GFS model of fibrosis;
vimentin transcripts were found increased in Tenon’s capsule over
the temporal development of scarring in rats [35]. Moreover, skp2
overexpression in the rabbit GFS model of fibrosis has also been
demonstrated and its downregulation by siRNA therapy rescues
Tenon’s capsule from bleb failure [36]. Furthermore, gene therapy
to increase abundance of p27Kip1 expression in the GFS rabbit
model has also shown protection against bleb failure [37]. Taken
together, the skp2-p27Kip1 pathway is likely a critical target for
anti-fibrotic modalities in GFS fibrosis, but whether vimentin
targeting affects this key cell proliferation signaling pathway in
GFS has remained untested.
The objective of this study was to identify a dose of WFA for
localized delivery that was effective at targeting soluble vimentin in
vivo and producing significant effects on the skp2-p27Kip1 pathway.
Towards this goal, we exploited the RbTCF cell culture model
[38] to first determine the concentration-dependent effects of
WFA on cell proliferation, differentiation and migration, and
interrogate WFA’s effects on the skp2-p27Kip1 pathway [7]. Our in
vivo proof-of-concept study used the rabbit GFS preclinical model
of surgical fibrosis [39]. Two doses of WFA differing by 10-fold
concentration were tested by localized delivery to differentially
target soluble vimentin over cytoskeletal vimentin-IFs. Here, we
report that fibrotic biomarker (skp2, p27Kip1 and a-SMA)
expression was differentially altered in manners similar to the
WFA dose-response found in cell cultures.
Methods
Reagents and general methods
WFA was purchased from Chromadex (Santa Ana, CA, USA).
Cell culture supplies were purchased from Life Technologies
(Grand Island, NY, USA) and cell culture plates from Thermo
Fisher Scientific (Pittsburgh, PA, USA), unless otherwise specified.
Mitomycin-C (MMC), and dimethylsulfoxide (DMSO) were
purchased from Sigma-Aldrich (Saint Louise, MO, USA).
Isolation and culture of Rabbit Tenon Capsule Fibroblasts
(RbTCFs)
To isolate RbTCFs, we followed established protocols with
minor modifications [40] [41]. Briefly, fresh young rabbit eyes
shipped overnight after sacrifice (Pel-Freez Biologicals, Rogers,
AR, USA), upon arrival, were washed three times with saline
solution containing an antibiotic-antimycotic cocktail and subcon-
junctival Tenon’s capsule tissues (10–15 mm2 approximate area of
each sample; n = 26 total) were dissected and transferred, in sterile
condition, to 60 mm culture plates. Each tissue was gently pressed
against the bottom of the plate and kept attached by placing a
sterile round glass coverslip on top of the tissue. Tissues were
overlaid with DMEM/F12 medium containing 10% fetal bovine
serum (FBS), L-glutamine and an antibiotic-antimycotic cocktail
(DMEM complete medium). Cultures were incubated at 37uC in a
humidified chamber maintained under 5% CO2 and cell culture
medium was replaced every 2 days. After 14 days in culture, when
numerous RbTCF cells had migrated out from the explants the
tissue pieces were carefully removed. RbTCF cells were allowed to
reach confluency and then sub-cultured for the designed
experiments. Cells were used before 6th passage.
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WFA treatment
RbTCF cells were plated at 50% confluence in 100 mm plates
in complete DMEM/F12 medium and allowed to attach for 4 h.
Cells were serum-starved in DMEM/F12 medium containing
0.1% FBS for 48 h and then treated with different doses of WFA
in the presence of serum (10% FBS) for 24 h. Soluble and
insoluble protein fractions were extracted for western blot analysis
as previously described [6]. For immunohistochemistry analysis,
cells were seeded into 8 well-glass slides in the presence or absence
of different concentrations of WFA for 24 h. Cells were fixed and
processed for fluorescence staining as described previously [6].
Cell culture scratch wound assay
RbTCF cells were seeded on 8-well-glass slides at 95%
confluency in DMEM/F12 complete medium and cells were
incubated for 24 h to allow to uniform covering of the glass well. A
cross-stripe scrape was made in each well, by using a 100 ml
micropipette tip and the floating cells and debris were gently
washed away. Adherent cells were incubated for 24 h in the
presence or absence of different concentrations of WFA or MMC
(15 mM), used as positive control. Cell migration was stopped at
24 h post-injury, when the control samples showed 95% closure of
the wound. Photographs were taken at 46magnification using an
inverted microscope (model CKX 41, Olympus America Inc.,
Center Valley, PA, USA) equipped with a digital camera (Q
Color3) at the time the scrape wound was introduced and 24 h
post-wounding. Images (n = 3/each treatment) were imported to
NIH ImageJ software and the empty cell-free gap of each wound
(perpendicular to the axis of injury) was measured at eight separate
spots at time 0 h, using as measurement unit the ‘‘scale bar’’ tool
in the ImageJ program. After 24 h, the thickness of the gap left
remaining between the two migratory edges of each wound was
measured again (n = 8). For each treated and control group, we
obtained 24 arbitrary values from which we calculated the average
and standard deviation using Microsoft Excel. To measure the
extent of cell proliferation contributing to wound closure, cell
cultures from 24 h post-injury samples were additionally subjected
to staining for Ki67 and counter stained with DAPI (as described
in Immunohistochemistry analysis section). DAPI-stained nuclei of
cells lining the wound margin as well as those that were within the
wound were counted in 6 independent fields for each treatment
condition.
Cell cycle analysis
For cell cycle analysis we followed a previously published
protocol (19) with some minor modifications. Briefly, RbTCF cells
were grown to confluence in 100 mm plates and growth-arrested
by serum starvation for 48 h in DMEM/F12 medium containing
0.1% FBS. Cells were trypsinized and seeded into 100 mm culture
plates at 60% confluency and allowed to attach for 2 h. Cells were
treated with vehicle (DMSO) or different concentrations of WFA
in the presence of serum (10% FBS) for 24 h and 72 h. Cells were
stained with 50 mg/ml propidium iodide and processed for flow
cytometric analysis following manufacturer’s protocol
Gel contraction assay
Collagen type I was extracted from rat tails [42] and formulated
as previously described [14]. Briefly, the ice-cold clear collagen
stock solution was neutralized with 0.2N NaOH, 50 mg/ml
NaHCO3 and 1:1000 diluted solution of acetic acid in 106
DMEM/F12 medium. This solution was immediately mixed with
RbTCFs at a concentration of 26105 cells/ml and 100 ml of the
collagen solution-cell mix was plated into a 96-well tissue culture
plate (n = 6 gels per treatment group). Gels were allowed to
polymerize in an incubator at 37uC with 5% CO2 for 30 min.
Polymerized gels were gently detached from the well sides and
different concentrations of WFA were added and gels cultured in
the presence or absence of recombinant human TGF-ß1 (2 ng/ml;
R&D Systems, Minneapolis, MN) well for 3 days. Gel contractile
activity was visualized at 106 magnification with the aid of an
inverted microscope, and digital images were imported to image-
management software (Photoshop; Adobe Systems, Mountain
View, CA) for evaluation and analysis.
In vitro myofibroblast transformation
RbTCFs were grown to confluence in 60 mm plates and
growth-arrested by serum starvation for 48 h in DMEM/F12
medium containing 0.1% FBS. After cell cycle arrest, cells were
trypsinized and replated in presence of serum (10%) in 100 mm
plates at 60% confluency. For western blot analysis, cells were
seeded in 100 mm plates at 60% confluence and for immunohis-
tochemistry analysis cells were seeded into 8-well glass slides. In
both sets of experiments, cells were allowed to attach for 3 h prior
to treatments. Cells were washed once with 16 PBS to remove
debris and floating cells. Cells were then treated with different
concentrations of WFA and cultured in the presence or absence of
TGF-ß1 (2 ng/ml) for 3 days. After 72 h treatment, cells were
prepared for western blot and immunohistochemical analysis as
described in the following sections.
Glaucoma filtration surgery in rabbit and WFA treatment
The animal experiments were conducted in strict accordance
with the Declaration of Helsinki, and under approved protocol
(Protocol number 2010-0682) by the Institutional Animal Care
and Use Committee of the University of Kentucky. All surgeries
were performed by the glaucoma clinical specialist (S.D.) who has
expertise in the rabbit model of glaucoma filtration surgery (GFS).
Anesthesia was employed during surgery and all efforts were made
to minimize animal suffering. New Zealand white male rabbits
weighing 2.5 to 3.0 kilogram each were employed in the study. All
animals were housed in separate cages under a 12 h light dark
cycle with food and water available ad libitum and showed normal
intraocular pressure (IOP) before the experimental procedure.
GFS was performed on both eyes: right eyes (n = 6) received
100 ml-WFA injections and left eyes (n = 6) received 100 ml-saline
injections (vehicle-treated samples). Rabbits were anesthetized
with ketamine-xylazine (25 mg/kg and 2 mg/kg, respectively). A
superior conjunctival flap was then created and a 22-gauge
cannula was inserted in the anterior chamber. The cannula was
secured with sclera using 8’0 prolene suture and conjunctival flap
was sutured using 8’0 vicryl. The cannula drains aqueous from the
anterior chamber under the conjunctiva thus creating filtering
bleb. Antibiotic and steroid eye ointment was placed in each eye at
the end of surgery. To investigate WFA’s targeting of soluble
vimentin in the GFS model, we compared the effects of two doses
(0.7 mg and 7.0 mg) that were directly injected under the
conjunctiva 4–5 mm above the filtering bleb. The WFA drug
formulations were freshly prepared as an emulsion in sterile saline
each day prior to injection, which was delivered above the
conjunctival bleb. Injections of WFA or vehicle were provided at
the end of the surgery (day 0) and subsequently, on days 4, 7, 14
and 21 after local topical application of tetracaine 1% eye drops.
Clinical eye examination, including assessment of bleb height, bleb
vascularity, corneal clarity and anterior chamber inflammatory
reaction, was conducted at d7, d14 and d21 post-surgery to obtain
useful information with respect to potential future drug efficacy
studies. Intraocular pressure was recorded at each time point
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under topical anesthesia using Tonopen-Vet (Reichert Inc.,
Depew, NY, USA). Bleb survival or failure was recorded at each
time point. Bleb was considered as failed if it was found to be flat,
highly vascularized or lacking any vascularization. Animals were
sacrificed on d28, whole eye globes enucleated and frozen at 280
uC until use. Tenon’s capsule biopsies were dissected from
uninjured (Control) eyes, and from GFS-injured eyes and tissues
prepared for western blot and immunohistochemical analyses.
Immunohistochemistry analysis
For immunostaining of cell cultures, cells were fixed in ice-cold
methanol for 5 min and then in acetone for 1 min at 220uC. After
a brief wash, cells were permeabilized/blocked in a 0.1% Triton
X-100 solution containing 1% albumin and 5% normal goat
serum for 1 h at 37uC. According to individual experiments, cells
were labeled with either rabbit anti-Ki-67 antibody (1:200, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or rabbit anti-
vimentin antibody (1:100, Abcam, Cambridge, MA, USA) for
18 h at 4uC in a background reducing solution (Dako North
America Inc., Carpinteria, CA, USA). Cells were then incubated
with goat anti-rabbit IgG secondary antibodies conjugated to
Alexa Fluor 488 (1:1000, Life Technologies, Grand Island, NY,
USA) at room temperature for 45 min. Nuclei were stained with
4,6-diamidino-2-phenylindole (DAPI, 1 mg/mL in 0.1 M PBS) for
10 min [6]. In some experiments, cells were also counterstained
with Phalloidin (1:500, Life Technologies, Grand Island, NY,
USA) for 1 h at room temperature. Digital images were acquired
on an Olympus IX81 microscope at 46 and 306 magnification
and were digitally deconvolved using AutoQuant Deconvolution
software (Olympus America Inc., Center Valley, PA, USA) to
improve image contrast and resolution [7]. Images were assembled
using Adobe Photoshop Software.
For immunostaining of rabbit tissues, samples were fixed in 4%
PFA, and then permeabilized/blocked in a 0.1% Triton X-100
solution containing 1% albumin and 5% normal goat serum for
1 h at 37uC. Samples were stained with mouse anti-vimentin
antibody (clone V9, 1:100, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) for 18 h at 4uC in a background reducing
solution (Dako North America Inc., Carpinteria, CA, USA). After
a brief wash, slides were incubated with goat anti-mouse IgG
secondary antibodies conjugated to Alexa Fluor 555 (1:500, Life
Technologies, Grand Island, NY, USA) for 45 min at room
temperature and counterstained with DAPI (1 mg/mL in 0.1 M
PBS) for 10 min. Digital images were acquired on an Olympus
IX81 microscope at 46and 306magnification and were digitally
deconvolved using AutoQuant Deconvolution software to improve
image contrast and resolution [7]. Images were assembled using
Adobe Photoshop Software.
Western blot analysis
For cell culture analysis, insoluble and soluble proteins were
extracted as previously described [6,7]. Equal amounts of protein
were subjected to SDS-PAGE on 4–20% gradient polyacrylamide
gels (Biorad, Hercules, CA, USA) and transferred to a PVDF
membrane. Blots were probed with mouse anti-vimentin antibody
(clone V9, 1:400, Santa Cruz Biotechnology), mouse anti-skp2
antibody (clone A-2, 1:200, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA), rabbit anti-p27kip1 antibody (1:200, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), and mouse anti-ß-
Actin antibody (clone AC-15, 1:20,000, Sigma-Aldrich, St. Louis,
MO, USA). After extensive washing and incubation with
respective secondary antibody conjugated to horseradish peroxi-
dase, the membrane was developed using chemiluminescent
reagents (Amersham, Piscataway, NJ, USA) and exposed to X-
ray films. Blots were scanned and band intensities quantified using
NIH ImageJ software and normalized to ß-actin levels.
For protein analysis from Tenon’s capsule tissues, soluble
proteins from each sample were extracted using methods
previously described [6]. Equal amounts of protein were subjected
to SDS-PAGE on 4–20% gradient polyacrylamide gels (Biorad,
Hercules, CA, USA) and transferred to PVDF membranes. Semi-
quantitative analysis by western blotting was performed and blots
were probed with mouse anti-a-SMA antibody (1:200, Dako),
mouse anti-vimentin antibody (clone V9, 1:400, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), mouse anti-skp2 antibody
(1:200, Santa Cruz Biotechnology Inc., Santa Cruz, CA), rabbit
anti-p27kip1 antibody (1:200, Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) and mouse anti-GAPDH antibody (1:1000,
Abcam, Cambridge, MA, USA). Blots were scanned and band
intensities quantified using NIH ImageJ software and normalized
to GAPDH levels.
Statistical analysis
The target validation proof-of-concept studies employed a
statistical evaluation scheme for pharmacodynamic (PD) measure-
ments of soluble vimentin expression as the end point, which was
made by western blot analysis. A significant change was defined by
expression levels of soluble vimentin attained 28 days after injury
that were increased by greater than 50% and that this change was
sufficient when compared to the baseline variation of this protein’s
levels in uninjured rabbit Tenon’s capsule. With these two criteria,
a 95% statistical confidence that the measured differences were
not due to chance variation was established. In addition, to
establish that drug-induced effects also accounted for biomarker
changes in Tenon’s capsule, we performed simultaneous compar-
isons with skp2, p27kip1 and a-SMA and defined the results to be
significant at P,0.05 using one-sided tests. Pearson correlations on
the log-transformed values were conducted to determine relation-
ships between proteins in injured tissue and WFA-treated samples.
The inverse relationship was used for p27kip1 because of the known
mechanism of skp2-dependent p27kip1 downregulation in ocular
injury repair [43].
Analysis of withaferin by liquid chromatography and
tandem mass spectrometry
Since Tenon’s capsule was employed for analysis of protein
biomarkers, we used remaining tissues of the anterior segment
such as the cornea, aqueous humor, ciliary body-iris and
conjunctiva [44] to estimate WFA tissue concentrations in close
proximity to the injection site. Tissue samples were incubated in
250 ml of water containing the internal standard (500 ng/ml), and
vortexed for 10 min. Subsequently, tissue samples were homog-
enized using a hand-held homogenizer (Tissue Tearor, Biospec
Products, Bartlesville, IL, USA). To this tissue homogenate, 750 ml
of ethyl acetate was added and vortexed for 20 min. Tissue
homogenates were centrifuged at 13,0006g for 10 min to separate
out the precipitated proteins. The supernatant was removed and
1 ml of fresh ethyl acetate was added to the tubes and vortexed for
20 min. Tubes were centrifuged again, and both supernatants
were transferred to glass tubes and the solvent was evaporated
using a nitrogen evaporator (Multivap, Organomotion, Berlin,
MA, USA) for 40 min. The residue was reconstituted in 0.25 ml of
acetonitrile and water (1:1) and transferred into LC-MS vials and
subjected for analysis. Prednisolone acetate was used as an internal
standard. WFA and prednisolone acetate were extracted from
rabbit ocular tissue (100 mg) by the ethyl acetate based protein
precipitation method [45]. The HPLC run conditions employed
10% acetonitrile-water gradient starting from 0 to 0.5 min,
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followed by an increasing acetonitrile gradient (10 to 90%) over
the next 6 min followed by a decreasing acetonitrile gradient (90
to 10%) at 8 min till the run completion at 9 min. Calibration
curve samples were prepared using choroid retinal pigment
epithelium (CRPE) tissue from untreated rabbit eyes obtained
from Pel-Freez Biologicals (Rogers, AR, USA). Extraction
recovery of WFA from these blanks was estimated at three
different (1, 10, and 100 ng/ml) concentrations using CRPE
tissue.
WFA concentrations in extracts from rabbit ocular tissue
samples were measured by means of electrospray ionization
MS/MS analysis using an API-4000 triple quadrupole mass
spectrometry (Applied Biosystems, Foster City, CA, USA)
following separation by HPLC. Analytes were separated on a
Zorbax C18, 4.1650 mm, 5 mm column using acetonitrile and
5 mM ammonium formate in water (adjusted to pH 3.5 with
formic acid) as mobile phase in gradient elution mode with a flow
rate of 0.40 ml/min. The total run time of analysis was 9.0 min.
Both WFA and prednisolone acetate were analyzed in positive
ionization mode.
Results
WFA targets soluble vimentin and inhibits cell cycle
progression in RbTCFs mediated by the skp2-p27kip1
pathway
Vimentin staining has been employed as a marker for Tenon’s
capsule fibroblasts [40], which is illustrated here in tissue sections
showing the abundant expression of this cytoskeletal protein
(Figure 1A). Primary cell cultures established from Tenon’s capsule
maintain a cytoskeletal vimentin expression pattern that is typical
for fibroblasts (Figure 1B). Next, to identify concentration-related
effects of WFA that cause perturbation of the vimentin-IF
cytoskeleton we investigated RbTCFs by immunostaining. At
higher concentrations (1 mM), WFA caused severe re-arrangement
of the vimentin network causing the peripheral vimentin-IFs to
collapse (Figure 2A–i) and condense around the nucleus. At low
concentrations (0 to 500 nM), WFA did not affect vimentin-IFs as
evidenced by their staining (Figure 2A–i, green). Since we had
previously shown in other cell types [5,6] that such higher
concentrations of WFA also interfere with F-actin, thought to
occur through vimentin-mediated association with filament-
binding partners [5,46], we performed staining with phalloidin
to examine F-actin. F-actin staining also remained intact at the low
concentrations of WFA (Figure 2A–ii, red), whereas, at the higher
WFA concentration of 1 mM, F-actin collapse was observed
primarily at the distal ends of the cytoplasm (Figure 2A–ii, arrows),
where the retraction of vimentin-IFs was prominent (Figure 2A–i,
arrowheads). Next, to determine WFA’s inhibitory activity on cell
cycle progression [6,14] we investigated the cytostatic mechanism
of WFA in RbTCFs. Growth-arrested RbTCFs induced to
proliferate in response to serum in the presence of WFA showed
distinct G0/G1 dose-related cell cycle inhibition (IC50 = 25 nM)
(Table 1). Previously, we had identified that the cyclin-dependent
kinase inhibitor p27kip1 is critical to WFA’s inhibition of cell
proliferation [7]; therefore, we also investigated the expression of
p27kip1 in RbTCFs by western blot analysis (Figure 2B). Prolif-
erating vehicle-treated cells expressed very low levels of p27kip1,
whereas, WFA treatment increased p27kip1 expression that
plateaued around 250 nM and reached maximal expression at
500 nM (Figure 2D). At 2 mM, WFA caused p27kip1 levels to
decrease strongly, which was associated with severe vimentin-IF
cytoskeletal perturbation and F-actin disintegration followed by
apoptosis (data not shown). Because of its critical role in the cell
cycle regulation of p27kip1 expression, we investigated the
expression of ubiquitin E3 ligase skp2 [47]. Skp2 expression levels
in vehicle-treated cells were clearly high (Figure 2B), as it is known
that skp2 expression becomes induced at G1 and remains high
through S/G2 [48]. Remarkably, WFA treatment at 250 nM
caused skp2 expression to be significantly downregulated and to
remain downregulated over the WFA-treatment dose curve
(Figure 2C). Together, these data show that WFA potently
interferes with the skp2-p27kip1 pathway to maintain inhibitory
control over the cell cycle at low concentrations.
WFA downregulates soluble vimentin and attenuates
TGF-b-induced myofibroblast differentiation in RbTCF
cells
Next we investigated the concentration-dependent activity of
WFA in RbTCFs on TGF-b-induced myofibroblast transforma-
tion. Interestingly, RbTCFs exposed to TGF-b1 (2 ng/ml) for 3
days induced the formation of spheroid-like cell agglomerates with
remarkable orchestration of sprouting filopodia that stained
positive for both vimentin (green) and a-SMA (red) (Figure 3A).
This phenotype revealed the successful transformation of RbTCFs
into myofibroblasts with a gain of invasive characteristics [13].
RbTCFs treated with TGF-b1 (2 ng/ml) in the presence of
500 nM WFA caused not only the fragmentation of filamentous
vimentin (Figure 3 C, higher inset panel, green, arrowheads), but
filopodia also had shorter protrusions (arrowheads) due to consid-
erable cytoskeletal effects on both vimentin-IFs (green, arrowheads)
and a-SMA (red, arrows) expression. To clarify whether the
perturbation of vimentin-IFs was due to targeting of soluble
vimentin by WFA, we also employed western blotting to analyze
the cellular soluble protein fractions. As seen in Figure 3D, WFA’s
targeting of soluble vimentin caused its downregulation that was
clearly evident at 125 nM, whereas, a-SMA expression remained
unperturbed. However, at 500 nM WFA, soluble vimentin was
completely downregulated, and a-SMA expression also showed a
10-fold reduction (Figure 3D). We previously had reported that
WFA downregulates a-SMA expression in rabbit corneal fibro-
blasts (RbCFs) when cultured in presence of TGF-ß1 [7], and
therefore, we compared these two types of ocular fibroblasts in
parallel. We found that RbCFs were about 6- to 8-times more
sensitive to WFA compared to RbTCFs when cultured in the
presence of TGF-ß1 (Figure 3D). Notably, corneal fibroblasts did
not form spheroid cell agglomerates when cultured in the presence
of TGF-ß1, although their competency to differentiate into
myofibroblasts remained unperturbed [7]. Finally, to test whether
WFA interfered with TGF-ß-induced contractile function in
Figure 1. Identification of RbTCF cells in vivo and in vitro.
Immunohistochemistry analysis of cell marker vimentin in rabbit
Tenon’s capsule tissue (B, red) and in isolated RbTCFs (A, green). Scale
bars: 100 mm in vitro (A), 50 mm in vivo (B).
doi:10.1371/journal.pone.0063881.g001
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RbTCFs, we also employed a collagen gel contraction assay using
RbTCFs (Figure 3F). We found that RbTCFs in presence of TGF-
ß1 contract collagen gels. WFA co-treatment at low concentrations
(250 nM) did not affect the contractile activity of RbTCF cells, but
significant attenuation of collagen gel contraction (over 80%
reduction) occurred when the concentration of WFA was
increased to 1 mM (Figure 3F). Together these data demonstrate
that soluble vimentin was more effectively targeted by WFA in
corneal fibroblasts in comparison to RbTCFs in presence of TGF-
ß1. Despite these cell type-sensitivity differences, RbTCFs acquire
greater sensitivity to WFA in the presence of TGF-ß1 compared to
serum treatment.
WFA potently downregulates cell migration
WFA is also known to inhibit cell migration [9,14] and a
number of studies have reported this activity occurs at concentra-
tions that are not toxic to cells [8,9,18]. Since cell migration is an
obligatory step during a wound healing response, we investigated
RbTCF cell migration in a culture model of wound closure to
determine WFA’s dose-response in this system. As shown in
Figure 4A, untreated RbTCFs were able to cover 95% of the
surface area left exposed from the scratch wound within 24 h. In
the presence of 250 nM WFA RbTCF cell migration into the
wound area was unaffected. However, significant inhibition of cell
migration occurred in samples treated with 1 mM and 2 mM WFA
(P,0.001). Importantly, even at the highest dose tested (2 mM) we
did not observe WFA-induced toxicities, which was evident from
absence of cell rounding and loss of cell attachment. In
comparison, MMC achieved similar levels of inhibition in the
scratch wound assay at concentrations 7-fold higher than that of
WFA (Figure 4B). Next, to ascertain that wound closure primarily
reflected cell migration we also stained RbTCFs for Ki67 to
examine the numbers of proliferating cells present in the wound
area (see Methods). As compared to vehicle treatment, 250 nM
WFA did not affect the numbers of DAPI positive nuclei found in
the wound area (P = 0.595). However, as anticipated, the 2 mM
WFA and 15 mM MMC treatments caused significant reduction
(2-fold; P,0.0001) in numbers of DAPI-positive cells in the wound
area. Remarkably, co-labeling for Ki67-positive nuclei in the
vehicle-treated condition revealed that only 5% of the DAPI nuclei
present in the wound area expressed this proliferation marker
(Figure 4C). WFA treatment caused a dose-dependent decrease in
numbers of these Ki67-positive cells to 2% at 250 nM (P,0.0001)
and to 1% at 2 mM concentration (P,0.0001) (Figure 4D). MMC
had a similar effect as 2 mM WFA on numbers of Ki67-positively
stained nuclei (P,0.0001). Taken together, our cell culture studies
identified a very potent inhibitory activity of WFA on RbTCF cell
proliferation and differentiation, whereas, blockade of cell
migration in RbTCFs required higher concentrations of WFA.
WFA potently targets soluble vimentin in Tenon’s
capsule and downregulates the skp2-p27kip1 pathway in
experimental glaucoma filtration surgery
Next, to validate that WFA was also effective in targeting
soluble vimentin in Tenon’s capsule in the GFS model of fibrosis,
we exploited a localized subconjunctival method for WFA delivery
as described in Methods. In Figure 5A, representative images of
injured Tenon’s capsule tissues, taken at high magnification (606),
revealed intense vimentin staining (red) localized primarily in the
enlarged cytoplasm of the resident cells (arrowheads). This finding
Figure 2. WFA’s cell cycle effects are regulated by the skp2-
p27kip1 pathway in RbTCF cells. (A) Representative images of
RbTCFs stimulated to enter the cell cycle after 48 h serum starvation.
Cells were stained with vimentin (green) and phalloidin (red) at 24 h
post-WFA treatment. WFA’s low concentration cell cycle activity does
not affect the vimentin-IF network (green). Vimentin-IFs become
affected only at higher concentrations (1 mM, arrow heads) and leads
to dismantling of the actin fibers (red) that are observed at the
periphery of cytoplasm (arrows). (B) Western blot analysis of skp2 and
p27kip1 expression in RbTCF cells at 24 h post-WFA treatment. C)
Densitometric quantification of skp2 (black) and p27kip1 (grey)
normalized to b-actin, using ImageJ software. Scale bars: 30 mm at
306magnification. * P,0.05 WFA vs control.
doi:10.1371/journal.pone.0063881.g002
Table 1. WFA potently arrests RbTCFs in G0/G1 phase.
Treatments S (%) G2/M (%) G0/G1 (%)
Control 0 h 0.00 6.97 93.03
Control 24 h 22.36 21.39 56.26
WFA 30 nM 8.01 13.18 78.81
WFA 62 nM 6.65 9.70 83.66
WFA 125 nM 2.17 2.64 95.19
WFA 500 nM 0.10 2.10 97.88
WFA 1 mM 2.24 1.60 96.16
# mean of two experiments.
doi:10.1371/journal.pone.0063881.t001
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revealed the transition of wound fibroblasts into the myofibro-
blastic phenotype, as revealed in comparison to the non-injured
control tissue that showed a typical spindle-like fibroblast shape
with constitutive levels of vimentin-IF staining. The high dose
(7 mg) WFA treatment caused potent downregulation of vimentin,
resulting in peri-nuclear condensation of vimentin-IFs and their
fragmentation represented as dot-like staining [5,6]. Notably, the
low dose (0.7 mg) WFA treatment did not produce any noticeable
effects on cytoskeleton vimentin-IFs.
Next the pharmacodynamic effects of the two WFA doses on
soluble vimentin expression were investigated by western blot
analysis. Proteins extracted in low salt buffer (soluble vimentin
fraction) [6] from injury-healing Tenon’s capsule tissues showed
increased levels of soluble vimentin in comparison to low baseline
levels found in uninjured eyes (6-fold increase; P,0.0012)
Figure 3. WFA prevents myofibroblast transformation and collagen gel contraction in RbTCF cells. Immunohistochemical analysis of
vimentin (green) and a-SMA (red) in RbTCF cells treated with TGF-b1 (2 ng/ml) for 3 days in presence and absence of WFA. (A) TGF-b1 treatment
induces formation of spheroid-like agglomerates (upper panels, 106magnification) with sprouting extensions positive for vimentin (green) and a-
SMA (red) (lower panels, 306 magnification). (B–C) WFA causes a dose-dependent downregulation of both vimentin (green) and a-SMA (red)
expression. Upon treatment with 500 nM WFA, cells form spheroids poorly (C, insert panels) and those that do form spheroids have shorter and
thinner extensions (C, arrowheads). Scale bars: 70 mm at 106magnification; 30 mm at 306magnification. (D) Western blot analysis of soluble vimentin
and a-SMA expression in RbTCF cells (left panel) and RbCF cells (right panel). (E) Densitometric quantification of vimentin (black and orange) and a-
SMA (grey and blue) in RbTCF cells and RbCF cells, respectively, normalized to GAPDH using ImageJ software. (F) Representative images of
polymerized collagen gels containing RbTCF cells (n = 6 gels per treatment group) treated with TGF-b1 (2 ng/ml) in presence and absence of different
doses of WFA for 3 days (106magnification). (G) Quantification of percentage of gel contraction normalized to the initial size of the gel. Data are the
mean of 2 independent experiments; Dotted circles represent the well’s area. *P,0.05 TGF-b vs WFA treated cells.
doi:10.1371/journal.pone.0063881.g003
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(Figure 5B). The 7.0 mg high WFA dose treatment targeted the
injury-induced expression of vimentin causing potent reduction of
soluble vimentin expression in Tenon’s capsule tissues, reducing
this to levels found in uninjured controls (6-fold reduction;
P,0.0005). Importantly, the 0.7 mg low WFA dose also signifi-
cantly reduced soluble vimentin expression (4-fold reduction;
P,0.0069) in Tenon’s capsule. These data afforded us next the
opportunity to validate biological relationships between WFA’s
binding target, soluble vimentin, and biomarker expression;
correlation and regression analysis on the log transformed values
revealed that biomarkers skp2 and a-SMA expression levels were
strongly correlated with soluble vimentin (R = 0.86604 and
R = 0.86727), respectively. Furthermore, there was also a strong
correlation for the inverse relationship between skp2 and p27Kip1
expression levels (R = 20.78; P = 0.013), revealing that WFA’s
downregulation of skp2 in Tenon’s capsule was protective of
p27Kip1 injury-induced downregulation. On the other hand, we
found that the lower WFA dose caused increased expression of
p27Kip1 in Tenon’s capsule (5.7-fold increase; P = 0.0012) with
only small further increase being observed at the high WFA dose
(6.7 fold; P,0.00005). In vehicle-treated injured tissues, a 3.4-fold
induction of a-SMA expression was observed (P = 0.0001), which
was potently reversed in injured tissues by the high WFA dose
(P,0.0001), reducing a-SMA expression levels to that found in
control samples (P = 0.1257). Interestingly, the low WFA dose also
reduced the injury-induced expression of a-SMA expression
(P,0.0001), however, this reduction was only moderate when
compared to effect of the high WFA dose. Taken together, we
established from these in vivo experiments that WFA potently
targets soluble vimentin in Tenon’s capsule in a dose-dependent
manner and exerts also effective control of the skp2-p27Kip1
pathway.
WFA’s effects on bleb survival
We also compared vehicle-treated injured eyes to those treated
with WFA for assessment of the extent of bleb appearance and
their survival at the times WFA injections were delivered
(Figure 6A). Vehicle-treated eyes had 100% bleb survival at one
week post-surgery, but by two weeks, all these blebs had failed.
WFA treatment at both the high and low dose showed equivalent
efficacy (100%) in extending bleb survival to two weeks (Figure 6B).
The extension of bleb survival by the low WFA dose at three weeks
post surgery did not reach statistical significance; however, 67% of
blebs treated with high WFA dose survived. All blebs treated with
both WFA doses failed at four weeks post-surgery. No adverse
responses to WFA in any of the drug treated eyes were detected
during the weekly clinical examinations. The intraocular pressure
remained normal and no cataract or corneal irritation was
observed.
Low-dose WFA subconjunctival injection provides
cytostatic drug concentrations in the anterior segment
Finally, to determine whether WFA delivery is maintained for a
week in tissues surrounding the site of injection, we measured
WFA levels in anterior segment tissues at one week after the last
dose in a weekly multiple dosing regimen using LC-MS/MS
analysis. The aqueous humor (Table 2) had the lowest WFA levels
(2.52 to 4.62 ng/g), whereas almost four-times higher levels of
WFA were retained in the conjunctiva (10.12 to 17 ng/g). WFA in
lens tissue was below the LC-MS detection limit (0.12 ng/ml).
Taken together, these data reveal that subconjunctival injection of
WFA at the low dose achieves a pharmacologically relevant
concentration that would maintain cytostatic activity over the
treatment period of 28 days in vivo.
Discussion
The principal finding of this study is the demonstration of
vimentin druggability in the GFS model of ocular fibrosis. Here,
we demonstrated that WFA dose-dependently targets soluble
vimentin to reduce its expression in Tenon’s capsule and inhibits
Figure 4. WFA inhibits cell migration in RbTCF cells. Scratch
wound assay in vitro. (A) Representative phase-contrast images of
RbTCF cells immediately after a cross-stripe scrape injury on a confluent
cell layer (0 h), 24 h post-wounding (Veh), and after treatment with
different concentrations of WFA. Mitomycin-C (MMC; 15 mM) was used
as positive control. (B) Arbitrary values of wound gap at 24 h
normalized to size of initial wound gap and calculated from two
independent experiments (n = 3 for each treatment group). *P,0.05
vehicle vs drug treated; ns = non-significant. (C) Quantification of total
numbers of DAPI nuclei per wound area at 24 h post-scratch injury
(**P,0.0001 vehicle vs drug treated) and Ki-67 positive cells (blue bars;
#P,0.0001 vehicle vs drug treated). (D) Fraction of Ki67 positive nuclei
in the wound area as a percentage of DAPI nuclei at 24 h post-scratch
injury. *** P,0.0001 vehicle vs drug treated.
doi:10.1371/journal.pone.0063881.g004
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expression of skp2, the ubiquitin E3 ligase that governs the
proteasome-mediated degradation of p27Kip1. This, as far as we
know, is the first demonstration of vimentin targeting by localized
delivery of WFA in vivo.
Vimentin is the principal type III IF protein expressed by
fibroblasts and its expression becomes increased after an injury
[28]. Moreover, vimentin-deficient fibroblasts are inept at fully
engaging the myofibroblast phenotype [49]. Consequently, injured
tissues of Vim KO mice show significant delay in myofibroblast
expression and have an impaired wound healing phenotype [28].
Moreover, a body of literature has shown that vimentin
overexpression occurs in different organs undergoing fibrosis
[50,51,52], yet, whether vimentin is a suitable pharmacological
target for surgical fibrosis had remained untested. The Tenon’s
capsule fibroblast cell culture model allowed us to clearly define
the dose-related effects of WFA on cellular processes linked to
injury repair. We identified that WFA potently targets RbTCF cell
proliferation in vitro, demonstrating that very low concentrations of
WFA (IC50 25 nM) affect G0/G1 cell cycle arrest. In this respect,
we found that WFA is about 2-fold more potent than MMC on
inhibiting RbTCF cell proliferation [38]. The cytostatic effect of
WFA confirms our previous results made in primary endothelial
cells, astrocytes, and corneal fibroblasts, and also relates to the in
vivo activity of WFA dosed at 2 mg/kg/d by i.p. injection resulting
in potent inhibition of pathological angiogenesis, gliosis, and
fibrosis in mice [5,6,7]. WFA’s cell cycle-targeting activity in
RbTCFs mediated through perturbation of the skp2-p27Kip1
pathway reflected that over 95% of cells were arrested in G0/G1
phase at 125 nM concentrations, while importantly, vimentin-IF
cytoskeletal integrity and cell shape changes were unremarkable.
This important result illustrates a concept that has not been as well
appreciated previously since most published reports on vimentin
have investigated the roles of polymeric vimentin focusing on its
role in cytoskeletal-related activities [24,25,27,28,53]. Considering
that soluble tetrameric vimentin is a minor fraction of the cellular
protein [1], its detection by immunohistochemical staining
methods is undoubtedly masked by the abundant cytoskeletal
vimentin-IFs. Trypsinization of cells effectively convert polymer-
ized vimentin to soluble vimentin; cell replating orchestrates the
process of vimentin polymerization and within a few hours the
vimentin-IF cytoskeletal structure is fully reestablished [54]. These
newly formed vimentin-IFs have cytoskeletal structures indistin-
guishable from those observed in unperturbed differentiated
mesenchymal cells, which underscores the dynamic nature of the
vimentin cytoskeleton. Freshly plated cells rapidly extend their
cytoplasm and incorporate tetrameric vimentin subunits into unit
length filaments that become detectable by microscopy first as tiny
dots and grow into squiggles that continue to extend laterally and
become compacted into long filament structures [55] in manners
mirroring polymerization of the purified protein [56]. These
Figure 5. WFA downregulates soluble vimentin and affects the skp2-p27kip1 anti-fibrotic pathway in an experimental glaucoma
filtration surgery model in rabbit. (A) Immunohistochemical analysis of vimentin expression (red) in Tenon’s capsule tissues at surgical sites 28
days post-injury (306magnification). Note the change in cell shape (arrowhead) in the injured sample (Veh) with abundant cytoplasmic vimentin
staining (red) as compared to uninjured sample (Cont) and the downregulation and fragmentation of vimentin-IFs in the high dose WFA-treated
sample. (B and E) Western blot analysis of representative tissues from Tenon’s capsule tissues extracts at 28 days post-injury showing expression
levels of vimentin, a-SMA, skp2 and p27kip1 in low-salt buffer extracts (soluble fraction). Blots were re-probed consecutively with antibodies. (C–D and
F–G) Densitometric quantification of soluble vimentin (black), a-SMA (grey), skp2 (shaded grey) and p27kip1 (shaded black) normalized to GAPDH, using
ImageJ software. Scale bars: 50 mm at 306magnification. *P = 0.0012 Cont vs Veh; **P = 0.0005 Veh vs WFA high dose; ***P = 0.0069 Veh vs WFA low
dose (Panel C). *P = 0.0001 Cont vs Veh; **P = 0.0001 Veh vs WFA high dose; ***P = 0.0001 Veh vs WFA low dose (Panel D). *P = 0.0001 Cont vs Veh;
**P = 0.00005 Veh vs WFA high dose; ***P = 0.0012 Veh vs WFA low dose (Panel F). *P = 0.0357 Cont vs Veh; **P = 0.0005 Veh vs WFA high dose;
***P = 0.0012 Veh vs WFA low dose (Panel G).
doi:10.1371/journal.pone.0063881.g005
Figure 6. Bleb appearance in representative rabbit eyes
subjected to GFS. (A) WFA treated eyes (top panels a–c; high dose)
and vehicle treated eyes (bottom panels d–f) at weeks 1, 2 and 3 post-
surgery. The arrows indicate the presence of the bleb and arrowheads
point to the cannula. Note the increased vascularization at two weeks
post surgery (e). (B) Kaplan-Meier bleb survival plot of rabbit eyes
treated with vehicle (solid line), low dose WFA (dotted line) and high
dose WFA (dashed line).
doi:10.1371/journal.pone.0063881.g006
Table 2. WFA distribution in anterior segment tissues.
Tissue
WFA
(range ng/g)
WFA
(mean ng/g)
WFA
(mean nM)
Aqueous humor 2.52–4.62 3.57 7.59
Cornea 4.29–7.80 6.04 12.85
Iris-ciliary body 6.07–11.37 8.72 18.55
Conjunctiva 10.12–16.99 13.55 28.82
doi:10.1371/journal.pone.0063881.t002
Withaferin A Targets Soluble Vimentin in Glaucoma
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e63881
nascent tetrameric and short multimeric forms of vimentin are
collectively considered the ‘‘soluble forms’’ because of their
solubility in low salt buffers. Collectively, these soluble vimentin
forms are highly sensitive to WFA activity in cell cultures and
become incorporated into the growing filament without affecting
IF polymerization, although the exact structural size of the in vivo
target of WFA has not been characterized. We have used
biotinylated WFA combined with streptavidin affinity chromatog-
raphy to demonstrate that WFA binds and isolates soluble
vimentin from cells [5], and this paradigm was extended also to
soluble GFAP [6], and most recently, to soluble desmin [7]
because of the highly conserved WFA binding site in their
respective rod 2B domains. Thus, during myofibroblast differen-
tiating WFA potently downregulated soluble vimentin and a-SMA
expression in RbTCFs at concentrations under 500 nM under-
scoring the sensitization of soluble vimentin to TGF-ß-driven
signaling events. Since TGF-ß stimulates vimentin gene expression
[57] that would also increase the pool of soluble vimentin, one
likely explanation for the increased sensitivity to WFA is the
greater abundance of soluble vimentin. On the other hand, in our
cell culture model of wound injury where less than 5% of cells
engage in cell proliferation, we found that WFA’s high concen-
tration-dependent blockade of wound repair was due to inhibition
of cell migration. Thus, our findings reveal that WFA exerts
several dose-related biological effects in RbTCFs at non-toxic
concentrations. These mechanistic findings from our cell culture
studies corroborate our previous in vivo studies made in the alkali-
induced model of corneal fibrosis that showed significant
modulatory effects by WFA on skp2, p27Kip1 and a-SMA
expression that resulted in enhanced corneal repair in mice at a
non-toxic WFA dose (2 mg/kg/d; intraperitoneal injection) [7].
Consequently, we sought similarly to identify the dose-response
relationship of soluble vimentin targeting by localized WFA
delivery in the clinically relevant rabbit model of GFS.
The design strategy to target soluble vimentin in rabbit eyes was
predicated on the binding mode of WFA to tetrameric vimentin
based on our prior molecular modeling studies [5]. WFA binds to
a highly conserved rod 2B region of the vimentin tetramer, where
a covalent bond occurs between the epoxide group of WFA and
the cysteine residue of the protein. We rationalize that native
tetrameric vimentin is bound covalently by WFA through two
discrete sequential steps. WFA binds initially with key amino acids
in the binding pocket through hydrophobic interactions made with
the polycyclic hydrocarbon chain backbone of the steroidal
lactone. Additionally, hydrogen bonding between glutamine and
aspartic acid with the A-ring groups of WFA are critical for activity
as their modification alleviates biological effects of the compound
[5]. Once WFA is oriented in the correct position via these
reversible interactions, a second irreversible binding event occurs
when the properly aligned nucleophilic cysteine of vimentin
attacks the C6-ß-epoxide of WFA. The remarkable stereospecific
requirement for attack on the C6-ß-epoxide predicts the correct
binding pose of WFA in the pre-alkylation complex, because the
close structural congener, 12-deoxowithastramonolide (12D-WS)
that also contains a reactive epoxide ring that is oriented instead in
the alpha-position, does not afford a covalent binding with
tetrameric vimentin. Consequentially, 12D-WS was found not to
possess the specific biological activities of WFA in in vitro and in vivo
assays [5,16]. Notably, prior results have also shown that WFA
concentrations even 10-fold higher than that (,3 mM) capable of
exerting significant vimentin-IF structural collapse and causing
apoptosis in cell cultures did not per se disrupt the formation of
vimentin-IFs in cell-free in vitro vimentin polymerization assays
[5,17]. Hence, WFA’s perturbation of vimentin-IFs in cell cultures
that occur at non-toxic submicromolar concentrations likely
engage complex intracellular regulatory mechanisms (e.g. phos-
phorylation or protein-protein interactions with chaperones),
which are known to govern the structural dynamics of this protein
class [53,58,59,60]. We believe that such interactions with diverse
co-associated proteins constitute a higher order of regulatory
control over vimentin’s filamentous dynamic behavior in cells. In
fact, known cytoskeleton vimentin-interacting proteins were
isolated using a WFA-biotin analog, which revealed that ß-actin
and ß-tubulin [5] as well as myosin (our unpublished data) co-
isolate with affinity tagged vimentin. These findings illustrate that
the vimentin-IF protein-interactome is both large and complex,
and that signaling events that alter cellular states can engage the
vimentin-IF cytoskeleton and affect its organization. For instance,
vimentin-IFs can dissemble and assemble their cytoskeletal
structures at lamellipodia [24] and filopodia [61] enabling these
mobile stress fiber scaffolds to rapidly respond locally to biological
cues. This suggests that the druggable soluble forms of vimentin
will be governed by their local abundance and temporal
regulation, which could be the critical pharmacodynamic aspects
of this class of IF protein target. In this respect, studies
investigating modalities that affect the mechanical properties of
cells have shown that cell softening induced by myosin perturba-
tion promotes the availability of soluble vimentin by depolymer-
izing polymeric vimentin-IFs, thereby exposing the vimentin
cysteine group to labeling by cysteine-reactive chemical probes.
However, in unperturbed stiff-cells due to low levels of soluble
vimentin the cysteine-reactive probe did not label cells due to the
predominantly polymeric forms of vimentin-IFs [62]. Taken
together, the idea advanced from our first part of this study that
helped define WFA’s dose-related targeting of soluble vimentin in
RbTCFs afforded us a rationalized mechanistic insight to probe
the vulnerability of the vimentin-skp2-p27kip21 axis to WFA
perturbation in vivo.
In this second part of the study, we ascertained that uninjured
rabbit eyes expressed stable low baseline levels of soluble vimentin
in Tenon’s capsule tissues. Hence, rabbit eyes subjected to GFS
that showed sustained high levels of soluble vimentin in Tenon’s
capsule post injury afforded us a model to investigate soluble
vimentin targeting in response to localized WFA treatment. Our
findings showed a dose-dependent reduction of soluble vimentin
after WFA treatment, and identified a pattern of p27kip1
expression that was similar to that in RbTCF cell cultures showing
maximal expression at low nanomolar concentrations. Indeed,
tissue concentrations of WFA achieved by localized delivery in the
anterior segment of rabbit eyes corresponded to an in vitro
concentration that caused G0/G1 cell cycle phase growth arrest in
cultured RbTCFs. Since reduction of skp2 levels was also achieved
by the low WFA dose in vivo, our data suggests that the skp2-
p27kip1 cell cycle pathway [43] was attenuated at this dose.
However, as the high WFA dose caused even more prominent
downregulation of skp2 and a-SMA, this suggested that other
mechanisms beyond inhibition of cell proliferation were involved
in mediating WFA’s high dose anti-fibrotic activity. In this respect,
skp2 has recently been shown to also regulate cell migration, which
occurs in a p27kip1-independent manner [63]. Skp2-deficient
embryonic fibroblasts were shown to be defective in cell migration
and this inhibition was overcome by re-introduction of recombi-
nant skp2 that lacked its nuclear localization sequence [64]. Thus,
cytoplasmic-localized skp2 was found not to interfere with nuclear
p27kip1 expression or regulate cell proliferation. Direct evidence
that skp2 activation is linked to fibrosis was shown in a kidney
fibrosis model, where increased levels of skp2, vimentin and a-
SMA were reported in fibrotic tissues [65]. In skp2 deficiency,
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injured mice were protected from fibrosis, which was correlated
with downregulated expression of both a-SMA and vimentin, and
increased expression of p27kip1 [65]. Given that pharmacologically
we have illustrated a similar attenuation of fibrotic biomarker
expression profile in injured Tenon’s capsule with WFA (reduced
vimentin, skp2 and a-SMA expression and increased p27kip1
expression) in GFS, we believe this anti-fibrotic molecular
signature is an attractive mechanism worthy of pursuit in
glaucoma surgery because it is also pharmacologically tractable.
Finally, our clinical observations made during the 4-week
investigation using the rabbit GFS model provided some
interesting preliminary results. Firstly, there was no incidence of
WFA-induced adverse effects, such as increased intraocular
pressure, cataracts, or corneal irritation in any of the rabbits
during drug treatment, suggesting that both doses of WFA were
well tolerated. Because WFA-treatment at both doses showed
equivalent bleb survival up to 2 weeks post-surgery, we wondered
if this was due to WFA’s anti-proliferative mechanism because it is
known that cell proliferation is most prominent at the early (1 to 2
week) stages of injury repair in GFS [66]. We rationalize that
WFA’s attenuation of cell proliferation would be readily achieved
at the lower dose. As there is indication that bleb survival was
extended further by the higher WFA dose, it is possible that at
later stages other mechanisms of the fibrotic repair process become
relevant that were not vulnerable to the low WFA dose. For
instance, during the 2 to 3 week period post-injury, myofibroblasts
become prominently elaborated in GFS [67]. During injury
healing, such contractile cells utilize cytoplasmic vimentin-IFs as
mechanical force-bearing structures to orchestrate coherent
cytoskeleton-mediated cell movement [28]. We rationalize that
the 10-fold higher WFA dose would likely interfere with the
cytoskeletal cell migratory machinery as we found only the high
WFA dose affected vimentin-IFs in vivo. In regards to this
mechanism, it was recently reported that polymeric vimentin IFs
contribute significantly to focal adhesion growth, endoplasm
spreading and cell motility, which are cellular mechanisms
involved in cell migration that were shown to be inhibited by
WFA [17,18] at concentrations considerably higher than WFA’s
anti-proliferative cytostatic dose [6,7,14]. Hence, we speculate that
attenuation of cell migration and cell contractile activity [68] of
myofibroblasts by the higher WFA dose may be linked to the
longer extension of bleb survival in GFS. This prospective idea
obviously requires further detailed investigation to define the
temporal and dose-related pharmacodynamic effects of WFA on
key molecular mediators of cell proliferation and migration that
are important for bleb survival in this GFS model.
This pilot in vivo study also has some limitations. First, solid
evidence to support that the higher WFA dose increases bleb
survival times will require greater numbers of rabbits to confirm
this pilot study. Second, the target and biomarker measurements
we made have used tissues that were obtained at terminal end
points and not at weekly stages when bleb survival was recorded.
This suggests that interpretations made on target druggability and
biomarker response relate only to states of the prevailing
pathophysiology of Tenon’s capsule at 28 days post injury, and
not directly to bleb survival. Indeed, experiments that assess target
and biomarker expression at each survival time point will need to
be performed. This will allow us to validate survival outcome with
biomarker protein expression characteristics that define WFA’s
mechanisms more accurately. Moreover, the retention of higher
concentrations of WFA in conjunctival tissues is consistent with the
hydrophobic nature of WFA and its affinity for lipid membranes.
The absence of detectable levels of WFA in lens is consistent with
the hydrophilic nature of abundant lens proteins and low affinity
of WFA for this richly proteinaceous tissue. The low levels of WFA
in aqueous humor are probably reflective of the free drug
concentrations in surrounding tissues. Thus, one may anticipate
that the highest therapeutic levels of WFA are achieved and
maintained in the conjunctiva and surrounding tissues including
Tenon’s capsule. However, low but significant WFA levels were
detectable in off target tissues also. As such, ophthalmic
toxicological studies have yet to be undertaken on WFA and any
potential side effects after prolonged treatment remain to be
determined. Our future studies will investigate target-related and
off-target effects of this inhibitor. As such, all these deficiencies of
the current investigation will require large-scale rabbit studies that
were beyond the scope of our pilot investigation. We believe the
data nevertheless is very informative for designing such future
studies as we have demonstrated for the first time vimentin
druggability using a localized delivery paradigm in rabbits. In
conclusion, our proof-of-concept investigation has provided
pivotal evidence that soluble vimentin in Tenon’s capsule is
druggable and this mechanism potently engages the skp2-p27kip1
pathway. Given that WFA has witnessed prolific interest lately
from diverse clinical areas of medicine for its vimentin-targeting
activity [6,8,9,10,69,70], the use of localized delivery methods for
WFA could offer additional insights into disease mechanisms
sensitive to vimentin chemical perturbation. Our findings illumi-
nate, additionally, the potential of developing localized delivery
methods to target other type III IFs (GFAP, desmin, peripherin)
where the overexpression of these homologous type III IFs has
been related to pathological processes such as reactive gliosis
[6,71,72] and related IF-mediated disorders [7,73,74].
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